Drug intelligence / Profile preview

VSV-HTLV-1 vaccine

Development stage: Unknown
Lead developer: StingInn
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

The VSV-HTLV-1 vaccine is a recombinant viral vaccine and immunotherapeutic developed by StingInn to prevent and treat Human T-cell Lymphotropic Virus type 1 (HTLV-1) infections and associated diseases. Utilizing a vesicular stomatitis virus (VSV) vector platform, the vaccine construct (VSV-gp62-ΔHT) expresses the HTLV-1 envelope glycoprotein (gp62) along with the regulatory proteins TAX and HBZ. This design aims to stimulate a robust immune response, including the production of neutralizing antibodies and the activation of cytotoxic T cells. The vaccine is being developed for indications such as Adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). StingInn has received STTR funding from NIAID and NCI to manufacture the vaccine for Phase I clinical trials.

Other names: recombinant VSV-HTLV-1VSV-HTLV-1 recombinant viral vaccineVSV-HTLV1 recombinant viral vaccineVSV-HTLV 1 recombinant viral vaccine

Targets

gp62 (HTLV-1 envelope glycoprotein gp62)Tax (HTLV-1 Tax)HBZ (HTLV-1 basic leucine zipper factor)HLA-A (HLA class I histocompatibility antigen A alpha chain)HLA-DRB1*15:01HLA-DR (Human leukocyte antigen DR)HLA-B

Beyond the preview

Go deeper on VSV-HTLV-1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSV-HTLV-1 vaccine.

Explore the full profile